SBIR Phase I: Viral Vectors for Low-Cost Peptide Production in Plants

SBIR 第一阶段：用于植物低成本肽生产的病毒载体

• 批准号: 9561380
• 负责人: Thomas Turpen
• 金额: $ 7.17万
• 依托单位: Biosource Technologies Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-02-01 至 1996-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9561380&HistoricalAwards=false
• 关键词: SBIR; Phase; Viral; Vectors; Low

9561380 Turpen The cost and availability of health care products based on peptides currently limit access to treatments. New methods are needed to produce pharmaceutical quality proteins such as subunit vaccines and antimicrobial peptides for human use on a large scale. This Small Business Innovation Research Phase I project will determine the feasibility of producing peptides in plants fused to the surface of viral particles. The approach of the small business Biosource Technologies, Inc. integrates the inexpensive synthesis of protein in plant biomass under non-sterile conditions with the design of an abundant, stable, and unique molecular structure that may easily be processed from plant extracts. This project offers important social and commercial benefits: By dramatically reducing production costs, this technology will enable vaccines and antibiotic peptides to be more accessible to a larger fraction of the world population who suffer from numerous infectious diseases. By making vaccines and antibiotic treatments more affordable, substantial new markets will be created world-wide for these low-cost, high-volume health care products.

9561380提高以多肽为基础的保健产品的成本和可获得性目前限制了获得治疗的机会。需要新的方法来大规模生产药用优质蛋白质，如亚单位疫苗和抗菌肽供人类使用。这个小型企业创新研究第一阶段项目将确定在融合到病毒颗粒表面的植物中生产多肽的可行性。小型企业Biosource Technologies，Inc.的方法将在非无菌条件下廉价地合成植物生物质中的蛋白质与设计丰富、稳定和独特的分子结构相结合，可以很容易地从植物提取物中进行加工。该项目提供了重要的社会和商业利益：通过大幅降低生产成本，这项技术将使疫苗和抗菌肽更容易为世界上更多患有多种传染病的人口所用。通过使疫苗和抗生素治疗更容易负担得起，将在世界范围内为这些低成本、大容量的保健产品创造大量新的市场。